Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer’s disease and strategies for treatment
Open accessAbstract
The blood-brain-barrier (BBB) has a major function in maintaining brain homeostasis by regulating the entry of molecules from the blood to the brain. Key players in BBB function are BBB transporters which are highly expressed in brain endothelial cells (BECs) and critical in mediating the exchange of nutrients and waste products. BBB transporters can also influence drug delivery into the brain by inhibiting or facilitating the entry of brain targeting therapeutics for the treatment of brain disorders, such as Alzheimer's disease (AD). Recent studies have shown that AD is associated with a disrupted BBB and transporter dysfunction, although their roles in the development in AD are not fully understand. Modulation of BBB transporter activity may pose a novel approach to enhance the delivery of drugs to the brain for enhanced treatment of AD. In this review, we will give an overview of key functions of BBB transporters and known changes in AD. In addition, we will discuss current strategies for transporter modulation for enhanced drug delivery into the brain.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Impaired function of these transporters accelerates Alzheimer's disease progression by limiting beta-amyloid clearance and promoting its accumulation in the brain.
“Impaired function of these types of transporters accelerates AD progression by limiting Aβ clearance and promoting its accumulation in the brain [20].”
From Advances in Strategies to Transport Nanoparticles Across the Blood–Brain Barrier for Drug Delivery into the Brain for the Treatment of Alzheimer’s Disease (2026) · cites this paper as [20]
Cites
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,294 · see citing works
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253 · see citing works
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954 · see citing works
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876 · see citing works
apoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · see citing works
The blood-brain barrier in aging and neurodegeneration
Knox, E. G., Aburto, M. R., Clarke, G., Cryan, J. F., & O’Driscoll, C. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01511-z · Cited by 738 · see citing works
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3966 · Cited by 689 · see citing works
Cirrito, J. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25247 · Cited by 660 · see citing works
Luissint, A.-C., Artus, C., Glacial, F., Ganeshamoorthy, K., & Couraud, P.-O. (2012) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-9-23 · Cited by 654 · see citing works
The impact of microglial activation on blood-brain barrier in brain diseases
da Fonseca, A. C. C., Matias, D., Garcia, C., Amaral, R., Geraldo, L. H., Freitas, C., & Lima, F. R. S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00362 · Cited by 572 · see citing works
Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier
Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81108 · Cited by 477 · see citing works
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399 · see citing works
Deane, R., Wu, Z., & Zlokovic, B. V. (2004) · Stroke · doi:10.1161/01.str.0000143452.85382.d1 · Cited by 392 · see citing works
Doens, D., & Fernández, P. L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-48 · Cited by 348 · see citing works
Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297 · see citing works
HDL and cholesterol handling in the brain
Vitali, C., Wellington, C. L., & Calabresi, L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu148 · Cited by 254 · see citing works
Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders
Qosa, H., Miller, D. S., Pasinelli, P., & Trotti, D. (2015) · Brain Research · doi:10.1016/j.brainres.2015.07.005 · Cited by 249 · see citing works
Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects
Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226 · see citing works
REST and neural gene network dysregulation in iPSC models of Alzheimer’s disease
Meyer, K., Feldman, H. M., Lu, T., Drake, D., Lim, E. T., Ling, K.-H., Bishop, N. A., Pan, Y., Seo, J., Lin, Y.-T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.023 · Cited by 216 · see citing works
Deo, A. K., Borson, S., Link, J. M., Domino, K., Eary, J. F., Ke, B., Richards, T. L., Mankoff, D. A., Minoshima, S., O’Sullivan, F., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.130161 · Cited by 193 · see citing works
Bellenguez, C., Charbonnier, C., Grenier-Boley, B., Quenez, O., Le Guennec, K., Nicolas, G., Chauhan, G., Wallon, D., Rousseau, S., Richard, A. C., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.07.001 · Cited by 166 · see citing works
Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders
Gil-Martins, E., Barbosa, D. J., Silva, V., Remião, F., & Silva, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107554 · Cited by 152 · see citing works
<i>ABCA7</i> frameshift deletion associated with Alzheimer disease in African Americans
Cukier, H. N., Kunkle, B. W., Vardarajan, B. N., Rolati, S., Hamilton-Nelson, K. L., Kohli, M. A., Whitehead, P. L., Dombroski, B. A., Van Booven, D., Lang, R., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000079 · Cited by 100 · see citing works
Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer’s disease
On behalf of the European Early-Onset Dementia (EU EOD) consortium, De Roeck, A., Van den Bossche, T., van der Zee, J., Verheijen, J., De Coster, W., Van Dongen, J., Dillen, L., Baradaran-Heravi, Y., Heeman, B., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1714-x · Cited by 74 · see citing works
A New Hypothesis for Alzheimer’s Disease: The Lipid Invasion Model
Rudge, J. D. (2022) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210299 · Cited by 58 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Sanadgol, N., Abedi, M., Hashemzaei, M., Kamran, Z., Khalseh, R., Beyer, C., & Voelz, C. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03528-2 · Cited by 109 · see citing works
Reed, S., Taka, E., Darling‐Reed, S., & Soliman, K. F. A. (2025) · Cells · doi:10.3390/cells14141064 · Cited by 71 · see citing works
“Other ABC transporters include the breast cancer resistance protein (BCRP) and multidrug-resistance-associated proteins (MRPs) [118].”
Recent advances in blood-brain barrier-on-a-chip models
Vetter, J., Palagi, I., Waisman, A., & Blaeser, A. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.03.041 · Cited by 55 · see citing works
Huang, N., Huang, Y., Deng, Z., Qi, S., Zhang, W., Liu, Y., & Tan, G. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5577 · Cited by 43 · see citing works
“Under normal physiological conditions, the BBB tightly controls the entry of substances into the brain parenchyma through paracellular and transcellular pathways, thereby preventing the infiltra‑ tion of harmful elements into the cNS and ensuring a stable internal environment (16,17).”
Brain Endothelial Cells in Blood–Brain Barrier Regulation and Neurological Therapy
Xiang, Y., Gu, Q., & Liu, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125843 · Cited by 42 · see citing works
The role of ABCG2 in health and disease: Linking cancer therapy resistance and other disorders.
El-Ashmawy, N., Al-Ashmawy, G., Hamada, O. B., & Khedr, N. (2024) · Life Science · doi:10.1016/j.lfs.2024.123245 · Cited by 16
Chagnot, A., & Montagne, A. (2025) · Current Biology · doi:10.1016/j.cub.2025.06.061 · Cited by 16 · see citing works
Li, L., Zhang, J., Zhang, Y., Zhao, R., Yang, F., Yan, Y., Wang, Q., & Xie, M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125112 · Cited by 13 · see citing works
Mi, X., Ye, Z.-L., Zhang, X., Chen, X., & Dai, X. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00751-2 · Cited by 11 · see citing works
“It can facilitate the excretion of many drugs from the brain tissues [53].”
Zhou, Y., Deng, Q., Vong, C., Khan, H., & Wai, S.-C.-A. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101823 · Cited by 9 · see citing works
Koppula, S., Wankhede, N. L., Sammeta, S. S., Shende, P. V., Pawar, R. S., Chimthanawala, N. M. A., Umare, M. D., Taksande, B. G., Upaganlawar, A. B., Umekar, M. J., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102389 · Cited by 10 · see citing works
Ahirwar, L. K., Blackburn, S., McBride, D. W., & Pandit, P. K. T. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03200-z · Cited by 11 · see citing works
“…essential amino acids, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) for drug ef fl ux, Organic Anion Trans-porting Polypeptides (OATPs) for organic anions, and Major Facilitator Superfamily Domain-containing Protein 2a (Mfsd2a) for Docosahexaenoic Acid (DHA) uptake [118 – 121].”
Chen, Y., Sun, X., Xi, Y., Luo, Z., Lai, H., Zhu, D., Zhang, Y., Xu, F., Li, J., Zhou, J., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.016 · Cited by 8 · see citing works
“These alterations especially the abnormal expression of BBB transporters disrupt the balance of A ß transport between the brain and peripheral compartments, leading to A ß accumulation and a vicious cycle of A ß deposition and BBB impairment 75 .”
Circulating exosomes with unique lipid signature in relapsing remitting multiple sclerosis
Palazzo, C., Asci, I., Russo, S., Buccoliero, C., Mangialardi, V., Abbrescia, P., Valente, O., Ruggieri, M., Paolicelli, D., Lobasso, S., et al. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1613618 · Cited by 7 · see citing works
“Moreover elevated LPC levels are often associated with BBB dysfunction, allowing more immune cells and serum factors to infiltrate the CNS, and with oxidative stress and lipid peroxidation, further damaging CNS tissue (Chaves et al., 2024).”
The Potential Role of Exosomes in Communication Between Astrocytes and Endothelial Cells
Czpakowska, J., Glabinski, A. R., & Szpakowski, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104676 · Cited by 7 · see citing works
“This type of transporters belongs to the ATP-binding cassette transporter (ABC) superfamily, which, with the solute carrier (SLC) superfamily, constitutes two of the most important groups [15,16].”
InfluentialBarrier breakdown: lung-brain crosstalk in systemic inflammation
Villalba, N., Beard, R. S., & Yuan, S. Y. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03807-1 · Cited by 6 · see citing works
“Additionally, the ABB and BBB express selective transport systems to facilitate nutrient supply from the blood to the brain while restricting the passage of harmful substances [18–20].”
Sissoko, C. A., Spitz, S., Zhang, Z., Abedi, K., Kamm, R. D., & Barrile, R. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115881 · Cited by 4 · see citing works
van der Panne, S. A., Durrant, H., Heuer, J. F., Kancheva, I. K., Stellingwerf, A., Verkaar, L., Verstappen, D., Mossel, P., Backes, W. H., Bakker, E. N. T. P., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71263 · Cited by 5 · see citing works
Cui, Y. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106106 · Cited by 5 · see citing works
Nutritional Modulation of Impaired Blood-Brain Barrier Integrity and Function in Major Depression
Adžić, M., Lukić, I., Mitić, M., Zerajic, E. F., Glavonic, E., Jovanović, M., & Ivković, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146917 · Cited by 6 · see citing works
“Key examples include [30]: SLC2A1/GLUT1, which transports glucose essential for brain energy; SLC59A1/Mfsd2a, critical for DHA (an omega-3 fatty acid) transport across the BBB; SLCO1A2/OATP1A2, involved in uptake of organic anions, hormones, and drugs; SLC22A8/OAT3, contributing to clearance of…”
Cruchaga, C., Timsina, J., Jiang, C., McCartney, D. L., Tao, F., Dalmasso, M. C., Najar, J., Anastasi, F., Ohlei, O., Puerta, R., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6597595/v1 · Cited by 4
“Given the primary role of SLCO1A2 is passive transport to the brain across the concentration gradient, we suspect that it contributes to disease process through decreased availability of substrates required for clearing tau tangle toxin in brain 40,41 .”
Peptide-Based Delivery Systems: Selected Insights into Cell-Penetrating Peptides
Adam, H., Abdollahi, S., & Musaimi, O. A. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00266 · Cited by 2 · see citing works
Kreutzer, E., Short, J. L., & Nicolazzo, J. A. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03731-0 · Cited by 4 · see citing works
“AD may result in impacts on central nervous system (CNS) drug exposure given alterations to the blood-brain barrier (BBB) have been reported, including changes to key drug transport systems [4].”
BackgroundSilva, R., Monteiro, J., Ramalho, M. J., Andrade, S., Loureiro, J. A., & Pereira, M. C. (2026) · Pharmaceuticals · doi:10.3390/ph19050685 · Cited by 2 · see citing works
“Impaired function of these types of transporters accelerates AD progression by limiting A β clearance and promoting its accumulation in the brain [20].”
Liu, C., Zhu, Z., Lin, H., Bush, W. S., Jenq, R. R., Cominelli, F., Pillai, J. A., Haines, J. L., Zhu, X., Xu, R., et al. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1735332 · Cited by 2 · see citing works
“…compromised, the BBB may contribute to AD by permitting neurotoxic substances and pro-inflammatory agents to access the brain and by impairing endothelial transport and clearance functions that are important for cerebral homeostasis (Sharma et al., 2022; Zhang et al., 2022; Chaves et al., 2023).”
Nanodelivery strategies for caloric restriction mimetics in age-associated neurodegeneration
Prabhu, P., Pai, V., & Singh, A. K. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103203 · Cited by 2 · see citing works
Nirmal, A. K., Dayalan, H., Rohith, S., & Ayyar, G. (2026) · Precision Nanomedicine · doi:10.33218/001c.157822 · Cited by 2 · see citing works
“…mimic endogenous substrates (e.g., glucose, amino acids) to exploit membrane transporters [12] Utilizes natural BBB transport pathways [12], [17] Limited by transporter size and capacity; competition with endogenous substrates [12] Passive Targeting Accumulation of nanoparticles…”
InfluentialExploring the landscape of targetable alterations in patients with glioblastoma
Aquilanti, E., Touat, M., French, P. J., Iavarone, A., Capper, D., Geurts, M., Rahman, R. M., Verhaak, R. G. W., Preusser, M., van den Bent, M. J., et al. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01190-7
“Selecting drugs with low affinity for these transporters 214 or combining targeted therapies with inhibitors of ABC transporters might enable improved drug delivery across the BBB, although previous attempts to do this have been unsuccessful for various reasons, including toxicities and suboptimal…”
Bis(styryl)benzene Probes for Targeting Early-Stage Amyloid-β Aggregates in Alzheimer’s Disease
GUTIERREZ, C. G., Mina, M., An, J., Bhowmik, S., Xu, K., Salaiza, J. A., Chen, K., Sayed, T. E., & Mirica, L. M. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00429 · Cited by 1 · see citing works
Vascularized tumor organoids as models for interpreting therapeutic response
Huang, S., Han, S., & Wang, K. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107673 · Cited by 1 · see citing works
The Role of Blood-Retinal Barrier in Retinal Neurodegenerative Diseases
Blankenborg, L., Anand‐Apte, B., & Biswas, S. (2026) · American Journal Of Pathology · doi:10.1016/j.ajpath.2026.05.002 · Cited by 1 · see citing works
Timsina, J., Jiang, C., McCartney, D. L., Tao, F., Dalmasso, M. C., Najar, J., Anastasi, F., Ohlei, O., Puerta, R., Yang, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71682-8 · Cited by 4 · see citing works
Wang, Z.-W., Wang, S., Wang, X.-Y., Zhang, Z., Li, W., Liu, Y., & Qi, H. (2025) · Journal of Environmental Science · doi:10.1016/j.jes.2025.12.032 · Cited by 1
Zhang, X., Hu, M., Li, Y., Yao, W. A. N. G., Zhen, R. O. N. G., & Ma, J. (2025) · 世界针灸杂志：英文版 · doi:10.1016/j.wjam.2025.01.002 · Cited by 2 · see citing works
Developing precision nanoparticle-based drug delivery systems for Alzheimer's disease therapy
Shan, Q., Zheng, W., Yao, W., Bai, Y., Ding, W., Wang, J., & Bai, F. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103789
Huang, Q., Zuo, Y., Xie, Y., Liu, Z., Wang, L., Xu, H., Yu, M., & Liu, C. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c01137
Viljoen, S. J., Chaves, J. C. S., Peall, I. W., White, A. R., & Oikari, L. E. (2026) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2026.126168
Self-citationAhmad, M., Aijaz, M., Ansari, M. A., & Afzal, M. (2026) · Metabolic brain disease · doi:10.1007/s11011-026-01960-3
“In particular, whether PE accumulation directly contributes to BBB destabilization or merely reflects broader metabolic dysfunction remains unresolved (Chaves et al. 2024).”
Recent progress of hydrogel-based strategies for CNS drug delivery.
Li, D., Liu, X.-T., & Liu, Y. (2026) · International journal of pharmaceutics · doi:10.1016/j.ijpharm.2026.127453
Song, N., Xing, H., Liu, F., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1939482
“Substrate selectivity is isoform-speci fi c: MCT1/MCT4 mediate monocarboxylates (e.g., lactate, SCFAs); LAT1/2 facilitate bidirectional exchange of tryptophan-derived kynurenine; and OAT/OATP families transport dicarboxylic acids such as succinate and bile acid derivatives (60).”
Mitochondrial control of blood-brain barrier homeostasis in neuroinflammatory psychiatric disorders
Pérez-López, L. M., Camacho-Morales, A., Álvarez, I. H., & Pérez‐Maya, A. A. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1924581
“…contributes to glutamine homeostasis within the brain interstitial space (Dolgodilina et al., 2016); In parallel, P-glycoprotein (P-gp) acts as a major efflux transporter that limits the accumulation of xenobiotics, metabolites, and pharmacological compounds within the brain (Chaves et al., 2024).”
Das, S. K., Mamatha, K., Nerune, S. M., Parveen, A., & Karak, P. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1895218
The sleep-deprived blood-brain barrier: Does the Brain's gatekeeper adapt or merely fail slowly?
Fluke, S. K., Hurtado‐Alvarado, G., Davis, C. J., Escobar, C., Guerrero‐Vargas, N. N., García-Páez, L. E., Ruíz‐Manzano, R., de Oca, A. C.-M., & Satterfield, B. C. (2026) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2026.100151
Mechanisms underlying cerebrovascular dysfunction in driving central nervous system diseases
Lu, J., & Xiao, Y. A. N. G. (2026) · Shengming kexue · doi:10.3724/cbls.2026129
Tahir, M. M., Liu, X., Yi, L.-S., Hou, X.-Q., Liao, Q., & Yu, H.-L. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12488-1
“At the BBB, efflux transporters such as ABCB1, ABCG2, and members of the ABCC family restrict the entry and accumulation of potentially neurotoxic sub-stances, whereas ABCA1, ABCG1, and ABCG4 primarily contribute to cholesterol and phospholipid homeostasis within the CNS [13, 27, 28].”
Bennett, K. R., Vanrobaeys, Y. S., Teboh, T., Smith, Z., Scott, A., Hajal, C., Hammond, P. T., & Straehla, J. P. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.71474
Lee, C., Park, D. H., Lee, E. J., Kim, S. H., Seong, Y.-J., Hwang, Y., Won, H., Choi, S. B., Ku, B., Lee, D. W., et al. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2676068
“Brain exposure is also strongly influenced by active efflux systems expressed at the BBB [19,20].”
Sharma, K., Singh, B., Mastana, S. S., Singh, M., & Singh, P. (2026) · Neurology International · doi:10.3390/neurolint18060114
“Efflux transporters, including P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), actively remove xenobiotics and metabolic waste, thereby contributing to neuro-protection [36].”
Veiga-Matos, J., Costa, I., Silva, R., & Remião, F. (2026) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2026.100604
Physical activity and the brain barriers: Mechanisms of neuroprotection and disease resilience
Morys, J., Solarz, A., Mi, J., Gilicinska, M., Kostka, M., Burek, M., Małecki, A., Toborek, M. J., & Nowacka-Chmielewska, M. M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119554 · Cited by 1 · see citing works
Qayyum, N., Song, W.-H., Wang, Y., Deng, D.-Z., Xie, Y.-T., Yuan, Q., & Guo, H.-H. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6c01621
Uti, D. E., Alum, E. U., Okpe, J. M., Egbung, J. E., & Mbah, J. O. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103524 · Cited by 1 · see citing works
Berdnikov, A. K., Сергеевич, А. А., Komleva, Y. K., Potapenko, I., & Salmina, A. B. (2026) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1450
“…cells of cerebral capillaries), which restricts penetration of hydrophilic molecules with molecular mass exceeding 400 Da into brain tissue and is mediated by the activity of a wide range of transporter proteins — for transfer of organic anions and cations, nucleosides, and nucleotides [5].”
Chen, Y., Zhao, X., Kassab, R., Elhefny, M. A., Yang, Y., Zheng, M.-Y., & Zhang, Q. (2026) · Journal of biochemical and molecular toxicology · doi:10.1002/jbt.70753
“Aβ can cross the blood‐brain barrier (BBB) through two main mechanisms: passive diffusion due to BBB disruption and active transport via the receptor for RAGE [25].”
Automated Microfluidic Platform for Molecular Transport Analysis across Biomimetic Interfaces
Fournier, O., Neves, M. A. D., Gavoille, T., Morin, A., Pais, B., Brenta, I., Lereculey‐Beaumanoir, J., Cruz, A., Santos, D. R. D., Oliveira, H. M., et al. (2026) · Advanced Sensor Research · doi:10.1002/adsr.202500166
Farouk, Y., Nagy, N., Amir, A. M. E., Madbouly, N. A., & El-Khazragy, N. N. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05789-w
Association Between ABCB1 Gene Polymorphisms and DrugResistant Epilepsy: an Integrative Review
Melo, M. M. C., Rodrigues, J. P. V., Silva, L. S., Santos, L. M., Varallo, F. R., de Moraes, N., & Pereira, L. R. L. (2026) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902026e25063
- Authors
- Chaves, J. C. S., Dando, S. J., White, A. R., & Oikari, L. E.
- Affiliations
- Queensland University of Technology (AU)
- Corresponding author
- Oikari, Lotta E.
- Venue
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Publisher
- Elsevier BV
- Published
- 2024-02
- Volume
- 1870
- Issue
- 2
- Pages
- 166967
- ISSN
- 0925-4439 (ISSN-L)
- OpenAlex
- W4388980096
- Cited by
- 62
- References
- 0
- Citations by year
- 2026: 37 · 2025: 17 · 2024: 8
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion, cc-by-nc-nd)
- Funders
- QIMR Berghofer Medical Research Institute
- National Health and Medical Research Council (1125796, 1118452)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- blood-brain barrier, BBB transporters, Alzheimer's disease, brain endothelial cells, brain drug delivery, blood-brain barrier disruption, transporter modulation, brain homeostasis
- MeSH terms
- Alzheimer Disease, Blood-Brain Barrier, Brain, Humans, Membrane Transport Proteins, Endothelial Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
